CD4 and neoplasm: In one of our experiments testing TR-CD4-cell response in a DP*04+ patient with exceptionally high-titer spontaneous anti-NY-ESO-1 serum antibody (reciprocal titers: > 10,000,000), we established a DP*04-binding NY-ESO-1157-170 peptide-specific CD4+ T-cell line and tested direct tumor recognition.